Log in

OTCMKTS:BCDABioCardia Stock Price, Forecast & News

$2.45
-0.05 (-2.00 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.40
Now: $2.45
$2.52
50-Day Range
$2.12
MA: $3.22
$4.32
52-Week Range
$2.01
Now: $2.45
$17.50
Volume167,500 shs
Average Volume94,190 shs
Market Capitalization$16.78 million
P/E RatioN/A
Dividend YieldN/A
Beta1.97
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.84 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BCDA
CUSIPN/A
Phone650-226-0120

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$630,000.00
Book Value$0.78 per share

Profitability

Net Income$-13,990,000.00
Net Margins-2,191.28%

Miscellaneous

Employees27
Market Cap$16.78 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BCDA News and Ratings via Email

Sign-up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.

BioCardia (OTCMKTS:BCDA) Frequently Asked Questions

How has BioCardia's stock been impacted by COVID-19 (Coronavirus)?

BioCardia's stock was trading at $3.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BCDA stock has decreased by 31.8% and is now trading at $2.45. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioCardia?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCardia in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioCardia.

How were BioCardia's earnings last quarter?

BioCardia Inc (OTCMKTS:BCDA) released its quarterly earnings data on Friday, May, 15th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by $0.26. The company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.17 million. BioCardia had a negative net margin of 2,191.28% and a negative return on equity of 423.10%. View BioCardia's earnings history.

What price target have analysts set for BCDA?

3 Wall Street analysts have issued twelve-month target prices for BioCardia's stock. Their forecasts range from $9.00 to $24.00. On average, they expect BioCardia's share price to reach $18.33 in the next year. This suggests a possible upside of 648.3% from the stock's current price. View analysts' price targets for BioCardia.

Has BioCardia been receiving favorable news coverage?

News articles about BCDA stock have been trending very negative recently, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioCardia earned a coverage optimism score of -3.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about BioCardia.

Who are some of BioCardia's key competitors?

What other stocks do shareholders of BioCardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCardia investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Marina Biotech (MRNA), Matinas BioPharma (MTNB), Cidara Therapeutics (CDTX), Sanofi (SNY), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX) and Novavax (NVAX).

Who are BioCardia's key executives?

BioCardia's management team includes the following people:
  • Dr. Peter A. Altman, CEO, Pres & Director (Age 52)
  • Dr. Eric Henricus J. Duckers, Chief Medical Officer (Age 51)
  • Mr. David McClung, VP of Fin. (Age 56)
  • Mr. Phil Pesta, VP of Operations (Age 53)
  • Dr. Ian McNiece Ph.D., Chief Scientific Officer (Age 65)

What is BioCardia's stock symbol?

BioCardia trades on the OTCMKTS under the ticker symbol "BCDA."

How do I buy shares of BioCardia?

Shares of BCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioCardia's stock price today?

One share of BCDA stock can currently be purchased for approximately $2.45.

How big of a company is BioCardia?

BioCardia has a market capitalization of $16.78 million and generates $630,000.00 in revenue each year. BioCardia employs 27 workers across the globe.

What is BioCardia's official website?

The official website for BioCardia is www.biocardia.com.

How can I contact BioCardia?

BioCardia's mailing address is 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA, 94070. The company can be reached via phone at 650-226-0120 or via email at [email protected]

This page was last updated on 7/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.